^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Endometrial Adenocarcinoma |
| Drug: | letrozole (Aromatase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
Published date:
03/02/2020
Excerpt:
She began letrozole 2.5 mg daily therapy for her ER-positive disease, while continuing intravenous zoledronic acid therapy….Since the initiation of combined letrozole-zoledronic acid therapy 30 months ago, the patient has had no evidence of disease progression on CT imaging every 6 months.
Secondary therapy:
zoledronic acid
DOI:
10.1016/j.gore.2020.100555
